Drug Profile

ASP 2390

Alternative Names: ASP-2390

Latest Information Update: 26 Apr 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Immunomic Therapeutics
Developer Astellas Pharma; Immunomic Therapeutics
Class Antiallergics; DNA vaccines; Insect allergy immunotherapies
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Allergic rhinitis

Most Recent Events

22 Apr 2022 Discontinued - Phase-I for Allergic rhinitis in Germany (Intradermal)
15 Sep 2020 Astellas Pharma re-initiates a phase I trial in Allergic rhinitis in Germany (Intradermal) (NCT04184895)
15 May 2020 Astellas Pharma terminates a phase I trial in Allergic rhinitis in Germany due to COVID-19 pandemic (Intradermal) (NCT04184895)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com